CL2014003590A1 - Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje. - Google Patents

Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje.

Info

Publication number
CL2014003590A1
CL2014003590A1 CL2014003590A CL2014003590A CL2014003590A1 CL 2014003590 A1 CL2014003590 A1 CL 2014003590A1 CL 2014003590 A CL2014003590 A CL 2014003590A CL 2014003590 A CL2014003590 A CL 2014003590A CL 2014003590 A1 CL2014003590 A1 CL 2014003590A1
Authority
CL
Chile
Prior art keywords
xbp1s
aav
cognitive
virus
optimization
Prior art date
Application number
CL2014003590A
Other languages
English (en)
Inventor
Flores Claudio Andrés Hetz
Bravo Gabriela Raquel Elena Martinez
Original Assignee
Univ Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chile filed Critical Univ Chile
Priority to CL2014003590A priority Critical patent/CL2014003590A1/es
Publication of CL2014003590A1 publication Critical patent/CL2014003590A1/es
Priority to PCT/CL2015/000069 priority patent/WO2016106458A1/es
Priority to EP15874441.7A priority patent/EP3254702B1/en
Priority to PL15874441.7T priority patent/PL3254702T3/pl
Priority to ES15874441T priority patent/ES2949828T3/es
Priority to US15/539,826 priority patent/US11400166B2/en
Priority to US16/858,435 priority patent/US20210060178A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2014003590A 2014-12-30 2014-12-30 Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje. CL2014003590A1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CL2014003590A CL2014003590A1 (es) 2014-12-30 2014-12-30 Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje.
PCT/CL2015/000069 WO2016106458A1 (es) 2014-12-30 2015-12-24 Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimización y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje
EP15874441.7A EP3254702B1 (en) 2014-12-30 2015-12-24 Aav/xbp1s-ha virus, gene therapy method and use thereof in the optimisation and improvement of learning, memory and cognitive capacities
PL15874441.7T PL3254702T3 (pl) 2014-12-30 2015-12-24 Wirus aav/xbp1s-ha, sposób terapii genowej i jego stosowanie w optymalizacji i poprawie zdolności uczenia się, pamięci i zdolności poznawczych
ES15874441T ES2949828T3 (es) 2014-12-30 2015-12-24 Virus AAV/XBP1S-HA, método de terapia génica y uso de este en la optimización y mejora de las capacidades de aprendizaje, memoria y cognitivas
US15/539,826 US11400166B2 (en) 2014-12-30 2015-12-24 AAV/XBP1s-HA virus, gene therapy method and use thereof in the optimisation and improvement of learning, memory and cognitive capacities
US16/858,435 US20210060178A1 (en) 2014-12-30 2020-04-24 Aav/xbp1s-ha virus, gene therapy method and use thereof in the optimisation and improvement of learning, memory and cognitive capacities

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2014003590A CL2014003590A1 (es) 2014-12-30 2014-12-30 Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje.

Publications (1)

Publication Number Publication Date
CL2014003590A1 true CL2014003590A1 (es) 2015-07-10

Family

ID=56283749

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003590A CL2014003590A1 (es) 2014-12-30 2014-12-30 Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje.

Country Status (6)

Country Link
US (2) US11400166B2 (es)
EP (1) EP3254702B1 (es)
CL (1) CL2014003590A1 (es)
ES (1) ES2949828T3 (es)
PL (1) PL3254702T3 (es)
WO (1) WO2016106458A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059554A1 (es) * 2015-10-09 2017-04-13 Universidad De Chile Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrófica
WO2017075729A1 (es) * 2015-11-04 2017-05-11 Universidad De Chile Virus aav/upr-plus, proteina de fusion upr-plus, metodo de tratamiento genetico y su uso en el tratamiento enfermedades neurodegenerativas, tales como la enfermedad de parkinson y huntington, entre otras

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2016003282A1 (es) * 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
US20220184175A1 (en) * 2019-02-01 2022-06-16 Universidad De Chile Treatment of aging or age-related disorders using xbp1
TW202115126A (zh) 2019-06-11 2021-04-16 美商舒爾人類基因療法公司 用於治療血漿激肽釋放酶失調所介導之疾病的抗體腺相關病毒載體遞送
EP3999647A1 (en) * 2019-07-18 2022-05-25 Lysogene Compositions and methods for the treatment of sanfilippo disease and other disorders
EP4048800A1 (en) 2019-10-23 2022-08-31 Shire Human Genetic Therapies, Inc. Adeno-associated virus vectors based gene therapy for hereditary angioedema
EP4263614A1 (en) 2020-12-16 2023-10-25 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
WO2023143435A1 (zh) * 2022-01-29 2023-08-03 上海日馨医药科技股份有限公司 表达tpk的重组病毒及其治疗阿尔茨海默病的用途
CN115779083B (zh) * 2022-08-05 2024-04-02 河南省精神病医院(新乡医学院第二附属医院) 下调Tp73蛋白表达的物质在制备治疗酒依赖的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090836B2 (en) 2002-06-21 2006-08-15 Institut Pasteur Vector for expressing α-L-iduronidase and method of treating MPS I by stereotactic injection into the brain of a mammal
WO2009034127A1 (en) 2007-09-12 2009-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the cyp46a1 gene for the treatment of alzheimer's disease

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059554A1 (es) * 2015-10-09 2017-04-13 Universidad De Chile Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrófica
US10512698B2 (en) 2015-10-09 2019-12-24 Universidad De Chile Method for genetic treatment using the AAV-XBP1s/GFP virus and use thereof in the prevention and treatment of amyotrophic lateral sclerosis
AU2016336063B2 (en) * 2015-10-09 2023-07-13 Universidad De Chile Method for genetic treatment using the AAV-XBP1S/GFP virus and use thereof in the prevention and treatment of amyotrophic lateral sclerosis
WO2017075729A1 (es) * 2015-11-04 2017-05-11 Universidad De Chile Virus aav/upr-plus, proteina de fusion upr-plus, metodo de tratamiento genetico y su uso en el tratamiento enfermedades neurodegenerativas, tales como la enfermedad de parkinson y huntington, entre otras
US10889831B2 (en) 2015-11-04 2021-01-12 Universidad De Chile AAV/UPR-plus virus, UPR-plus fusion protein, genetic treatment method and its use in treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, among others
US11795476B2 (en) 2015-11-04 2023-10-24 Universidad De Chile AAV/UPR-plus virus, UPR-plus fusion protein, genetic treatment method and its use in the treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, among others

Also Published As

Publication number Publication date
WO2016106458A8 (es) 2021-12-23
ES2949828T3 (es) 2023-10-03
US20170360961A1 (en) 2017-12-21
EP3254702A1 (en) 2017-12-13
US20210060178A1 (en) 2021-03-04
US11400166B2 (en) 2022-08-02
WO2016106458A1 (es) 2016-07-07
EP3254702B1 (en) 2023-05-10
PL3254702T3 (pl) 2023-09-11
EP3254702A4 (en) 2019-02-20

Similar Documents

Publication Publication Date Title
CL2014003590A1 (es) Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje.
CL2016002364A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas
ZA201605114B (en) Modified biological control agents and their uses
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
BR112017007160A2 (pt) sistemas de catalisador de fosfinimida de titânio e de iminoimidazolidida de titânio com suportes de ativador.
DK3143138T3 (da) Betinget aktive biologiske proteiner
CL2016001921A1 (es) Proteínas inmovilizadas y uso de las mismas
CL2018002543A1 (es) Anticuerpos gitr, metodos y usos.
BR112017026559A2 (pt) ceratoprótese e usos dos mesmos.
DE112016005759A5 (de) Gleichdruckmehrkammerbehälter, thermodynamischer energiewandler und betriebsverfahren
DK3393579T3 (da) Øjenbehandlingssystem
BR112017007282A2 (pt) métodos, sistemas e processos de montagem de novo de leituras de sequenciamento
DK3669886T3 (da) Knoglemorfogenetiske proteiner
ES2899185T8 (es) Cepas probióticas que tienen capacidad de absorción de colesterol, procedimientos y usos de las mismas
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
HK1244145A1 (zh) 在控制節點中使用的方法和相關的控制節點
DK3484599T3 (da) Oprensningsfremgangsmåde og anvendelser deraf
BR112017019373A2 (pt) método implementado por computador, e, mídia legível por computador
DK3227430T3 (da) Svampeværtsstammer, dna-konstruktioner og fremgangsmåder til anvendelse
CL2016001961A1 (es) Levadura biológica, procedimiento de obtención y usos
DE112015006553A5 (de) Zylindrische Massagerolle und Massageset
TH176299B (th) วิธีการบำบัดทางชีวภาพและชุดเครื่องบำบัดทางชีวภาพ
TWI844533B (zh) 研磨液、研磨液套組及研磨方法
TH1601005119A (th) จุลชีพที่รีคอมบิแนนท์ที่มีการแสดงออกของอะเวอร์เมคตินอะนาล็อก และการใช้ของพวกมัน
TH1601002465A (th) สารเตรียมแขวนลอยที่เป็นน้ำและการใช้ของสิ่งเหล่านี้ดังปุ๋ยทางใบ